Prospective observational investigation of possible correlations between change in FVC and change in cough or dyspnea scores using the living with pulmonary fibrosis questionnaire (L-PF) between baseline and after approximately 52 weeks of nintedanib treatment in patients suffering from chronic fibrosing ILD with a progressive phenotype. (INREAL)

24/11/2020
28/09/2026
EU PAS number:
EUPAS38272
Study
Finalised
Documents
Study protocol
Initial protocol
English (273.63 KB - PDF) View document
Updated protocol
English (615.13 KB - PDF) View document
Study results
Study results
English (448.23 KB - PDF) View document
Study report
No information provided.
ENCePP Seal
No information provided.